Blog Archives

Blog

Tips to Use Phoenix WinNonlin More Efficiently

Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…

CertaraNovember 7, 2022

Blog

The Role of PBPK Modeling & Simulation in Infants & Neonates

Many factors make it challenging to obtain adequate pediatric samples for use in drug development…

CertaraNovember 4, 2022

Blog

Why you should select your drug formulation before starting clinical studies

Drug developers often rush through the discovery process to get into human testing. Most are…

CertaraOctober 28, 2022

Blog

PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside

Next generation therapeutics Oligonucleotide drugs are unique among therapeutic modalities in that they don’t engage…

CertaraOctober 14, 2022

Blog

The Growing Value of Quantitative Systems Pharmacology (QSP)

Gain a foundational understanding of QSP in this 101-level article with examples of QSP applied…

CertaraOctober 7, 2022

Blog

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D)…

CertaraOctober 4, 2022

Blog

Calculate on the cloud

In order to increase the flexibility, access and integrability, Calculators and Predictors have been made…

CertaraOctober 3, 2022

Blog

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

For the first time, the European Medicines Agency (EMA) has passed new regulations to help…

CertaraSeptember 27, 2022

Business transparency, integrity or data disclosure concept, businessman standing with disclosure financial document in crystal clear fish bowl

Blog

EU-CTR Challenges Drug Developers Faced in the First 6 Months

Under European Union Clinical Trial Regulation 536/2014 (EU-CTR), replacing the EU Clinical Trial Directive (Directive…

CertaraSeptember 26, 2022

Blog

3 Takeaways from the FDA Oligo Guidance You Need to Know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…

CertaraSeptember 23, 2022

Blog

Tips to Use Phoenix WinNonlin More Efficiently

The Role of PBPK Modeling & Simulation in Infants & Neonates

Why you should select your drug formulation before starting clinical studies

PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside

The Growing Value of Quantitative Systems Pharmacology (QSP)

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

Calculate on the cloud

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

EU-CTR Challenges Drug Developers Faced in the First 6 Months

3 Takeaways from the FDA Oligo Guidance You Need to Know

Newsletter sign up

Quick links

Solutions

Contact